Epidemiology and Institutional Treatment Distribution of Patients With Myelofibrosis (MF) in Germany: Insights From a Real-World Evidence Study
Author(s)
Lisa Merker, MSc, Dorothea Plundrich, PhD, Nadine Müller, M.A., Francisco Henriquez, MSc, Stefan Schilling, M.A., Markus Rückert, PhD.
TriNetX Oncology GmbH, Freiburg im Breisgau, Germany.
TriNetX Oncology GmbH, Freiburg im Breisgau, Germany.
OBJECTIVES: To estimate incidence and prevalence of MF in Germany and assess institutional treatment variations.
METHODS: An epidemiological survey was conducted to estimate the number of diagnosed and treated patients in HY1 2022. Estimations are based on a health care structure analysis (HCSA) from 2020, which identified care-relevant institutions across Germany from the annual hospital quality reports published by GBA. The survey results were used to generate 1-year estimates of treated MF prevalence and incidence for Germany in 2022.
A representative sample was built for a retrospective chart review of patients with MF treatment in 2021, capturing their entire treatment history since initial MF-diagnosis.
RESULTS: The HCSA identified 346 care relevant MF treating centers in Germany. 45 institutions participated in the epidemiological survey, providing prevalence and incidence data on 818 MF patients in HY1 2022. The institutionally weighted prevalence projection resulted in an estimated total prevalence of 5115 patients in HY1 2022 (including WAW) with an institutional distribution of 76% office-based practices/medical care centers (OBP/MCC), 9% non-university hospitals (NUH) and 14% university hospitals (UH). The treated prevalence in HY1 2022 was 3391 patients (72% OBP/MCC, 10% NUH, 18% UH). The ratio of 1/3 WAW vs. 2/3 treated patients is consistent with previous reporting. 26% of the total prevalence were reported as incident patients. The estimates for the full year 2022 ranged from 4273 to 6445 prevalent and from 1111 to 1676 incident patients.
54 institutions participating in the chart review contributed retrospective data from 350 patients (78% OBP/MCC, 15% NUH, 7% UH) on the patient journey from diagnosis to current therapy status.
CONCLUSIONS: The real-world study provides current epidemiological data and treatment patterns for myelofibrosis in Germany. The estimates fall into the upper half of formerly reported ranges. Patient care is dominated by OBPs and MCCs.
METHODS: An epidemiological survey was conducted to estimate the number of diagnosed and treated patients in HY1 2022. Estimations are based on a health care structure analysis (HCSA) from 2020, which identified care-relevant institutions across Germany from the annual hospital quality reports published by GBA. The survey results were used to generate 1-year estimates of treated MF prevalence and incidence for Germany in 2022.
A representative sample was built for a retrospective chart review of patients with MF treatment in 2021, capturing their entire treatment history since initial MF-diagnosis.
RESULTS: The HCSA identified 346 care relevant MF treating centers in Germany. 45 institutions participated in the epidemiological survey, providing prevalence and incidence data on 818 MF patients in HY1 2022. The institutionally weighted prevalence projection resulted in an estimated total prevalence of 5115 patients in HY1 2022 (including WAW) with an institutional distribution of 76% office-based practices/medical care centers (OBP/MCC), 9% non-university hospitals (NUH) and 14% university hospitals (UH). The treated prevalence in HY1 2022 was 3391 patients (72% OBP/MCC, 10% NUH, 18% UH). The ratio of 1/3 WAW vs. 2/3 treated patients is consistent with previous reporting. 26% of the total prevalence were reported as incident patients. The estimates for the full year 2022 ranged from 4273 to 6445 prevalent and from 1111 to 1676 incident patients.
54 institutions participating in the chart review contributed retrospective data from 350 patients (78% OBP/MCC, 15% NUH, 7% UH) on the patient journey from diagnosis to current therapy status.
CONCLUSIONS: The real-world study provides current epidemiological data and treatment patterns for myelofibrosis in Germany. The estimates fall into the upper half of formerly reported ranges. Patient care is dominated by OBPs and MCCs.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH79
Topic
Epidemiology & Public Health
Disease
Oncology